C-Reactive Protein and Frailty in Heart Failure

Ribeiro, Édina Caroline Ternus; Sangali, Tamirys Delazeri; Clausell, Nadine Oliveira; Perry, Ingrid Schweigert; Souza, Gabriela Corrêa

doi:10.1016/j.amjcard.2021.11.018

Cited by 10 publications

(11 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Boxer et al found that CRP levels are negatively correlated with the 6-min walk distance in HF patients with LVEF less than 40% [ 76 ]. Ribeiro et al reported that frailty, assessed by the physical and multidimensional approach, was significantly associated with only high sensitivity CRP among several inflammatory and humoral biomarkers in outpatients with HF aged ≥ 60 years [ 77 ]. These findings suggest that CRP is a promising sarcopenia and frailty biomarker in HF patients, and further studies should seriously consider inflammation as a possible pathophysiological pathway for frailty in HF patients.…”

Section: Biomarkers Of Frailty and Sarcopenia In Hfmentioning

confidence: 99%

Sarcopenia and Frailty in Heart Failure: Is There a Biomarker Signature?

Sato

Vatic

Fonseca

et al. 2022

Curr Heart Fail Rep

View full text Add to dashboard Cite

Purpose of Review Sarcopenia and frailty are common in patients with heart failure (HF) and are strongly associated with prognosis. This review aims to examine promising biomarkers that can guide physicians in identifying sarcopenia and frailty in HF. Recent Findings Traditional biomarkers including C-reactive protein, aminotransaminase, myostatin, and urinary creatinine as well as novel biomarkers including microRNAs, suppression of tumorigenicity 2 (ST2), galectin-3, and procollagen type III N-terminal peptide may help in predicting the development of sarcopenia and frailty in HF patients. Among those biomarkers, aminotransferase, urinary creatinine, and ST2 predicted the prognosis in HF patients with sarcopenia and frailty. Summary This review outlines the current knowledge of biomarkers that are considered promising for diagnosing sarcopenia and frailty in HF. The listed biomarkers might support the diagnosis, prognosis, and therapeutic decisions for sarcopenia and frailty in HF patients.

show abstract

Section: Biomarkers Of Frailty and Sarcopenia In Hfmentioning

confidence: 99%

Sarcopenia and Frailty in Heart Failure: Is There a Biomarker Signature?

Sato

Vatic

Fonseca

et al. 2022

Curr Heart Fail Rep

View full text Add to dashboard Cite

show abstract

“…Of the included studies, 13 studies were considered of having a high risk of bias [ 7 , 31 , 32 , 39 , 41 , 43 , 46 , 52 , 53 , 60 , 61 , 63 , 64 ], 16 as moderate risk of bias [ 18 , 29 , 33 , 36 , 37 , 42 , 44 , 45 , 48 – 50 , 55 , 56 , 58 , 59 , 62 ], and 12 studies had a low risk [ 28 , 30 , 34 , 35 , 38 , 40 , 47 , 51 , 54 , 57 , 65 , 66 ] (Table S2).…”

Section: Resultsmentioning

confidence: 99%

Association between natriuretic peptides and C-reactive protein with frailty in heart failure: a systematic review and meta-analysis

Prokopidis,

Ishiguchi,

Jordan

et al. 2024

Aging Clin Exp Res

View full text Add to dashboard Cite

Background Heart failure (HF) and frailty are accompanied by a bidirectional relationship, sharing common risk factors including elevated levels of natriuretic peptides and inflammation. The aim of this study was to compare biomarkers associated with poor clinical outcomes, that is, plasma brain natriuretic peptide (BNP), N-terminal-pro B-type natriuretic peptide (NT-proBNP), and C-reactive protein (CRP) in patients with HF and frailty vs. patients with HF without frailty. Methods From inception until July 2023, PubMed, Scopus, Web of Science, and Cochrane Library a systematic literature search was conducted. To evaluate whether frailty is linked with greater levels of BNP, NT-proBNP, and CRP, a meta-analysis using a random-effects model was used to calculate the pooled effects (CRD42023446607). Results Fifty-three studies were included in this systematic review and meta-analysis. Patients with HF and frailty displayed significantly higher levels of BNP (k = 11; SMD: 0.53, 95%CI 0.30–0.76, I2 = 86%, P < 0.01), NT-proBNP (k = 23; SMD: 0.33, 95%CI 0.25–0.40, I2 = 72%, P < 0.01), and CRP (k = 8; SMD: 0.30, 95%CI 0.12–0.48, I2 = 62%, P < 0.01) vs. patients with HF without frailty. Using meta-regression, body mass index (BMI) and age were deemed potential moderators of these findings. Conclusions Frailty in HF is linked to increased concentrations of BNP, NT-proBNP, and CRP, which have been epidemiologically associated with adverse outcomes. The increased risk of NYHA III/IV classification further emphasizes the clinical impact of frailty in this population.

show abstract

“…Overall, the quality of the included studies was considered moderate ( Supplementary Table 3 ), for which three studies measuring the prevalence of polypharmacy had some concerns in relation to the risk of bias[ 20 , 21 , 25 ]. In terms of number of medications, the overall quality of the studies was evaluated as low ( Supplementary Table 4 ), albeit one study had some concerns[ 14 ].…”

Section: Resultsmentioning

confidence: 99%

What is the association of polypharmacy with frailty in heart failure? A systematic review and meta-analysis

Prokopidis,

Testa,

Veronese

et al. 2024

JFSF

View full text Add to dashboard Cite

This systematic review and meta-analysis aimed to explore the differences in the number of prescribed medications and polypharmacy risk between patients with heart failure (HF) and frailty vs. those with HF but without frailty. Eligible studies included observational or experimental studies in patients aged ≥50 years. Thirteen studies met the criteria and were included in the final analysis. Patients with frailty and HF exhibited a higher risk of polypharmacy (OR: 1.87, 95% CI 1.72 – 2.04, I 2 = 0%, P < 0.01) compared to those without frailty. Results remained significant after adjusting for comorbidity status. Additionally, patients with frailty and HF were prescribed more medications compared to those without ( k = 6; MD: 1.43, 95% CI 0.31 – 2.55, I 2 = 94%, P = 0.01), with a high degree of heterogeneity. However, results were non-significant after adjustment for comorbidity status. Patients with HF and frailty have a higher need of polypharmacy compared to those without frailty, which may increase the risk of potentially inappropriate medications (PIM). Investigating the real-world prevalence of PIM may support clinicians in their routine assessment as part of a comprehensive management strategy in patients with HF and frailty.

show abstract

C-Reactive Protein and Frailty in Heart Failure

Cited by 10 publications

References 27 publications

Sarcopenia and Frailty in Heart Failure: Is There a Biomarker Signature?

Sarcopenia and Frailty in Heart Failure: Is There a Biomarker Signature?

Association between natriuretic peptides and C-reactive protein with frailty in heart failure: a systematic review and meta-analysis

What is the association of polypharmacy with frailty in heart failure? A systematic review and meta-analysis

Contact Info

Product

Resources

About